Why Revolution Medicines (RVMD) Stock Is Down Today

Revolution Medicines (RVMD) is down 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is that investors are taking profits after a huge run-up rather than reacting to clearly negative company-specific news. Revolution Medicines just announced another Phase 3 milestone, but that update may not have been enough to push shares higher after the stock’s sharp gains following its recent drug approval and other pipeline advances.

Details:

On October 5, the company said it began treating patients in the Phase 3 RASolute 309 study testing RASONQUE plus zoldonrasib as a first-line treatment for metastatic RAS G12D pancreatic cancer.

In mid-September, the company disclosed Breakthrough Therapy designation for RASONQUE in combination with chemotherapy for first-line metastatic pancreatic cancer, reinforcing momentum in the franchise.

In late August, RASONQUE won U.S. approval in metastatic pancreatic cancer, giving Revolution Medicines its first approved product and shifting the company into the commercial stage.

This could be because expectations are already very high: the stock had already delivered a very large year-to-date gain by early October, so even favorable pipeline progress may have triggered a sell-the-news response.

Sources:

Revolution Medicines, Yahoo Finance, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RVMD Insider Trading Activity

$RVMD insiders have traded $RVMD stock on the open market 109 times in the past 6 months. Of those trades, 0 have been purchases and 109 have been sales.

Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:

MARK A GOLDSMITH (See Remarks) has made 0 purchases and 22 sales selling 230,008 shares for an estimated $40,352,843.
STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 11 sales selling 102,275 shares for an estimated $20,486,119.
MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 11 sales selling 104,967 shares for an estimated $16,883,735.
LORENCE H. KIM has made 0 purchases and 14 sales selling 73,090 shares for an estimated $14,967,124.
JEFF CISLINI (SVP & General Counsel) has made 0 purchases and 10 sales selling 63,182 shares for an estimated $13,070,226.
ANTHONY MANCINI (See Remarks) has made 0 purchases and 17 sales selling 33,550 shares for an estimated $6,212,172.
ELIZABETH M ANDERSON has made 0 purchases and 5 sales selling 10,143 shares for an estimated $1,958,015.
ALAN B. SANDLER (Chief Development Officer) has made 0 purchases and 7 sales selling 6,650 shares for an estimated $1,343,234.
JACK ANDERS (Chief Financial Officer) has made 0 purchases and 3 sales selling 6,775 shares for an estimated $1,232,469.
SUSHIL PATEL has made 0 purchases and 9 sales selling 5,580 shares for an estimated $1,048,967.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive RVMD Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$RVMD Hedge Fund Activity

We have seen 452 institutional investors add shares of $RVMD stock to their portfolio, and 202 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DARWIN GLOBAL MANAGEMENT, LTD. added 8,418,804 shares (+380.8%) to their portfolio in Q2 2026, for an estimated $1,576,673,613
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,878,385 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $913,623,942
CAPITAL WORLD INVESTORS added 4,008,244 shares (+inf%) to their portfolio in Q2 2026, for an estimated $750,663,936
FMR LLC added 3,736,108 shares (+44.1%) to their portfolio in Q2 2026, for an estimated $699,698,306
JPMORGAN CHASE & CO added 3,298,066 shares (+inf%) to their portfolio in Q2 2026, for an estimated $617,661,800
BLACKROCK, INC. added 2,483,084 shares (+22.1%) to their portfolio in Q2 2026, for an estimated $465,031,971
WELLINGTON MANAGEMENT GROUP LLP removed 2,184,404 shares (-36.2%) from their portfolio in Q2 2026, for an estimated $409,095,181

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$RVMD Price Targets

Multiple analysts have issued price targets for $RVMD recently. We have seen 14 analysts offer price targets for $RVMD in the last 6 months, with a median target of $195.0.

Here are some recent targets:

Michael Schmidt from Guggenheim set a target price of $235.0 on 07/09/2026
Robert Burns from HC Wainwright & Co. set a target price of $195.0 on 07/06/2026
Joseph Catanzaro from Mizuho set a target price of $215.0 on 07/06/2026
Robert Driscoll from Wedbush set a target price of $181.0 on 07/02/2026
Gregory Renza from Truist Securities set a target price of $210.0 on 06/30/2026
Ami Fadia from Needham set a target price of $235.0 on 06/29/2026
Cory Kasimov from Evercore ISI Group set a target price of $220.0 on 06/10/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.